A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

Health Secretary Robert F. Kennedy Jr., who has often linked vaccines to the neurodevelopmental disorder autism, said ...

Nigeria's second-largest pharmaceutical company, GlaxoSmithKline (GSK), announced its exit from the country, ending its 51-year presence.Three months later, Sanofi, another leading pharmaceutical ...

Ohio and Indiana are suing the makers of a popular heartburn medication, saying the drug company concealed cancer risks and ...

The pharma sector was spared from Trump's sweeping tariff plan last week, which kicked in on Wednesday, but the U.S. president had previously pledged to impose tariff on pharma products and his ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...

ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

GSK pays ABL Bio $49.5M upfront for blood-brain barrier platform access, with potential $2.67B in milestone payments. Deal ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...